endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

Flag­ship takes a rare knock as cell re­place­ment start­up based on Bob Langer tech gets slapped with clin­i­cal hold

4 years ago
FDA+

With Lenti­Glo­bin cleared by FDA, blue­bird lifts EU mar­ket­ing hold on gene ther­a­py us­ing the same de­liv­ery mech­a­nism

4 years ago
Cell/Gene Tx

J&J, Sid Mukher­jee's Vor team up to pair bis­pecifics with en­gi­neered stem cells for blood can­cer

4 years ago
Deals
R&D

A bright fu­ture for LAG-3? Top an­a­lysts see an arms race in the mak­ing, but drug­mak­ers need a bi­ol­o­gy break­through

4 years ago
R&D

Eli Lil­ly makes mod­est bet on 'all-in-hu­man' dis­cov­ery out­fit for ALS drugs, deep­en­ing bid in pre­ci­sion neu­rol­o­gy

4 years ago
Deals

Ax­el Hoos, the keep­er of the on­col­o­gy flame at Glax­o­SmithK­line, steps away for his next chal­lenge at tiny Scor­pi­on

4 years ago
People

Spurring a biotech craze of its own, the UK plots out pub­lic-pri­vate in­vest­ment plan as part of $1B+ in­dus­try ...

4 years ago
Financing

Eli Lil­ly, Boehringer In­gel­heim tout piv­otal heart fail­ure win for Jar­diance, po­ten­tial­ly set­ting up a No­var­tis ...

4 years ago
R&D
Pharma

Chi­nese health au­thor­i­ty erects new gold stan­dard in on­col­o­gy R&D, spook­ing in­vestors in boom­ing field

4 years ago
China

The CRO mad­ness con­tin­ues as Gold­man Sachs-backed buy­er group shells out $8.5B for Parex­el

4 years ago
Deals
R&D

Ar­row­head rocked by an­i­mal tox is­sues again, hit­ting the pause but­ton on RNAi study in cys­tic fi­bro­sis

4 years ago
R&D

WuXi will add 500 jobs at Delaware man­u­fac­tur­ing cam­pus as it looks to bol­ster its CD­MO arm

4 years ago
Outsourcing
Manufacturing

Kin­tara of­fers peek at mid-stage da­ta in re­lapsed glioblas­toma pa­tients; Jazz wins quick ap­proval for pe­di­atric ...

4 years ago
News Briefing

An­oth­er re­pur­posed drug bites the dust in Covid-19 as An­gion bails on or­gan dam­age drug ef­fort

4 years ago
R&D
Coronavirus

Say good­bye to plants: Syn­bio play­er An­theia earns new back­ers in quest to re­design flo­ra-de­rived med­i­cine ...

4 years ago
Financing

Al­tim­mune aban­dons ship on in­tranasal Covid-19 vac­cine, re­fo­cus­ing on liv­er, obe­si­ty pro­grams af­ter tri­al flop

4 years ago
R&D
Coronavirus

Gold­man Sachs backs clin­i­cal tri­al ser­vices in the cloud with $230M eq­ui­ty play amid de­cen­tral­ized study craze

4 years ago
Financing

Sanofi in­vests in the fu­ture of mR­NA with plan to pump bil­lions of dol­lars in­to next-gen cell ther­a­py busi­ness

4 years ago
R&D
Cell/Gene Tx

Sanofi kicks off PhII test for RIPK1 in­hibitor, trig­ger­ing De­nali mile­stone; Ital­ian biotech flops key end­point in ...

4 years ago
News Briefing

Gilead­'s Kite earns sec­ond-line win for CAR-T Yescar­ta, set­ting up a bat­tle over ear­li­er blood can­cer pa­tients

4 years ago
R&D
Pharma

EQRx and Ex­sci­en­tia, a pair of self-styled dis­rup­tors, team up to over­turn the drug pric­ing ap­ple cart

4 years ago
Deals

Arie Bellde­grun's Vi­da Ven­tures goes back to the well with $825M mega­fund and its eyes set on more in­no­v­a­tive meds

4 years ago
Financing

Ar­cus de­clares cryp­tic in­ter­im win for close­ly watched an­ti-TIG­IT drug, but you'll have to wait for the da­ta

4 years ago
R&D

A pair of for­mer MIT re­searchers think they've un­locked the next gen­er­a­tion of mR­NA us­ing syn­bio 'log­ic cir­cuit­s'

4 years ago
Financing
Startups
First page Previous page 78910111213 Next page Last page
A service from the Financial Times